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A 44 year-old woman took six mercuric bichloride tablets (3.0 gm.)
and entered the hospital with nausea and abdominal cramps three hours
later. Her blood pressure was 86/60. Five hours after the ingestion of
the poison, BAL treatment was begun and she was given 2 cc. every
four hours for six days, and then 1 cc, every 12 hours for five days.
During the first 42 hours the patient had diarrhea, vomited and suffered
abdominal cramps. Fifty cc. of urine were passed in the first 24 hours,
then none for five days. The urinary output rose slowly for six days to
935 cc. and then fell to an average of 120 cc. until death. The NPN on
the second day was 53 mg. per cent rising to 450 on the 28th day. On the
29th day she died, clearances of inulin, creatinine and PAH were
infinitesimal on six occasions.
[Abbreviations: BAL, British antilewisite or dimercaprol; NPN,
nonprotein nitrogen (normal, 22—29mg per cent); PAH, para-aminohip-
purate.]
Discussion
DR. F. GARY TOBACK (Department of Medicine and Cell
Physiology, and Professor of Medicine and Cell Physiology,
University of Chicago, Chicago, Illinois): This case, taken from
the landmark paper on nephron structure in acute renal failure
by Jean Oliver, Muriel MacDowell, and Ann Tracy, was
published in 1951, before the dialysis era began [1]. It is a brief
chronicle of the relentless, malignant course of untreated mer-
curic-chloride-induced tubular necrosis. Despite the abnormal
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metabolic setting that accompanies death from uremia, a micro-
dissected nephron from this patient's kidney showed exuberant
focal proliferation of tubular epithelial cells (Fig. 1). The
surprising observation made 40 years ago that the regenerating
nephron can contain collections of growing cells that project
into the tubular lumen or interstitium has been confirmed by
others [2—4]. What factors mediated the proliferation of renal
epithelial cells in the disordered, catabolic internal milieu of this
patient with acute renal failure? Is focal tubular cell multiplica-
tion evidence that growth-stimulatory factors were released
locally by renal cells? If so, cellular mediators produced in the
injured, but healing, nephron might contribute to reepithelial-
ization after tubular necrosis.
The relationships among renal cell dysfunction, morphologic
damage, and impairment of glomerular filtration and renal blood
flow in acute renal failure are poorly understood [5]. There are
occasional examples in humans, and many more among exper-
imental animal models, in which extensive tubular cell necrosis
is associated with failure of renal function. Often, however, this
is not the case. Renal tissue from many patients does not exhibit
significant abnormalities at biopsy or autopsy despite oliguria;
this finding suggests that injury to the renal epithelium often
causes cellular dysfunction but not necrosis. When structural
injury is present, it probably serves more as a guide to the
severity of the lesion than as a marker of specific biochemical
pathways that are disrupted and that are responsible for cellular
dysfunction. Important biochemical abnormalities in acute re-
nal failure are a reduction in the cytosolic concentration of ATP
and an increase in cytosolic calcium, alterations in the cytoskel-
eton, generation of free radicals, and reduced protein synthesis
[61. How a specific ischemic or toxic insult to the kidney
induces biochemical perturbations that result in a marked
reduction in GFR, a lesser decrement in renal blood flow, and
oliguria is not clear. If the injury is mild, structural changes may
not be apparent at the light microscopic level. If the insult is
more severe, alterations such as sloughing of proximal tubular-
brush-border microvilli can occur that are rapidly reversed after
adequate blood flow returns. If the injury is of sufficient
intensity and/or duration, cell death ensues. In most patients
with acute failure of glomerular filtration, cellular dysfunction
appears to be more important than frank structural damage
because the two structural lesions found most consistently in
humans, loss of microvilli and necrosis of individual tubular
epithelial cells, are found relatively infrequently [7].
When a renal insult induces both nonlethal injury of some
cells and necrosis of others, recurrent insults probably continue
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Fig. 1. Portion of a microdissected nephron from the patient who died
of mercury-induced acute rena/failure. The terminal medullary portion
of a proximal convoluted tubule is shown. The cortical portion of this
convolution showed the typical nephrotoxic necrosis due to mercury.
This lesion is visible in the horizontal stretch of the tubule at point A, an
intact basement membrane outlining the dead mass of dark stained
necrotic debris. At B there begins a long segment of tubule, greatly
swollen, in which the basement membrane has disintegrated completely
and the tubule wall is destroyed. The tubular destruction ends abruptly
(C) and the convolution continues, its basement membrane intact, to
the passage into the thin portion of Henle's loop. At the point of
greatest disruption (B'), irregular regeneration of the epithelium is
evident in the clusters and masses of cells with large vesicular nuclei. It
is also evident that this regeneration has failed to repair the tubule wall
or reestablish a lumen, this failure apparently due to lack of an intact
basement membrane to direct the course of the proliferating cells
(magnification x 82). Insert B' shows the disruptive lesion at B'
(magnification x 200).
Insert A shows a typical nephrotoxic tubular lesion in the terminal
segment of a proximal convolution of a nephron from the kidney of a
dog that had received an intravenous injection of 75 mg of corrosive
sublimate. The renal epithelium is completely necrotic and reduced to
granular debris. Note the intact basement membrane, at places out of
focus and therefore invisible, which maintains the tubular contours
(magnification x 200). (Reproduced from Ref. I by copyright permis-
sion of the American Society of Clinical Investigation.)
the regenerative process [8]. A schematic response to renal
injury is presented in Figure 2. At the subcellular level, mito-
chondrial swelling and blebbing of the endoplasmic reticulum
occur, and the proximal tubular brush border can undergo
sloughing. In the plasma membrane, loss of protein orientation
and alterations in phospholipid content occur, such that Na/K-
ATPase is displaced from its normal basolateral position to the
apical surface of the cell with loss of barrier function of the
plasma membrane [9]. At the cytoskeletal level, gaps in the
terminal web of actin microfilaments develop, and actin redis-
tributes in the cytoplasm [9]. If the intensity and/or duration of
the insult is limited, the cell becomes dysfunctional but sur-
vives. Injury that is more severe, however, probably leads to
detachment of the cell from the tubular basement membrane,
before or after necrosis. This analysis suggests two therapeutic
strategies: one designed to facilitate recovery of cells after
nonlethal injury, and a second designed to stimulate prolifera-
tion of noninjured and surviving injured cells that recovered to
replace those dead cells that detached. Polypeptide factors that
induce hyperplasia of renal epithelial cells have been identified
[10], and these factors might play a role in the repair of
nephrons after acute injury and necrosis (Fig. 2, pathway 1).
Mechanisms that repair nonfatally injured cells (Fig. 2, pathway
2) are not well defined, although recovery of this population of
cells is of major importance in the healing process. How repair
of injured cells and proliferation to replace necrotic ones result
in restoration of normal glomerular filtration and renal blood
flow remains uncertain.
In this Nephrology Forum, I will focus attention on mecha-
nisms that mediate cellular regeneration after tubular necrosis.
Prescott has shown that, under physiologic conditions, nearly 2
x 106 tubular epithelial cells, about one cell per human neph-
ron, slough into the urine each day [11]. Some proliferation
therefore is required under normal circumstances to replace the
lost cells and to maintain structural integrity of the kidney. In
acute renal failure, injury increases the rate of cell loss beyond
the capacity of basal physiologic proliferative mechanisms to
keep pace and to maintain nephron integrity. To restore renal
structure and function, recovery must take place despite the
retention of toxins and nitrogen, acidosis, electrolyte imbal-
ance, anemia, hypervolemia, and a severely curtailed intake of
nutrients. That restoration does occur demonstrates the ex-
traordinary capacity of renal cells to regenerate. Renal repair
and regeneration are anabolic processes that must occur in the
setting of systemic catabolism. Although rarely stated, the
therapeutic principle that underlies the management strategy in
acute renal failure is that the kidney heals itself when support-
ive care such as dialysis is provided. Another strategy exists:
acceleration of the pace of regeneration by provision of nutri-
ents such as amino acids and by the administration of growth
factors [12]. The rationale for this strategy lies in the observa-
tion that the rate of renal regeneration is ordinarily suboptimal
because systemic hypercatabolism increases the body's de-
mand for calories and nutrients, while at the same time, the
adverse effects of renal failure on renal excretory and gastroin-
testinal function decrease the supply of those nutrients. The
role of dialysis is to correct acid-base, electrolyte, and volume
imbalances and to remove retained toxins so that the extracel-
lular environment for renal cellular repair is more favorable.
Provision of nutrients, calories, and growth factors could re-
verse the catabolic state, permit accelerated repair of injured
renal tissue, and thereby speed recovery. I believe that we
should focus on developing and implementing this strategy in
the next decade [12].
Rats with mercuric chloride-induced acute renal failure man-
ifest stimulated synthesis of cellular protein, nucleic acids, and
r 
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Fig. 2. Renal epithelial cell repair after acute injury. A renal insult such as hypoxia can affect the cytosol, organelles, and plasma membrane. Cells
can be uninjured, nonlethally injured, or killed. Dead cells could be replaced by proliferation of noninjured cells and/or nonlethally injured cells
that have recovered (pathway 1). Nonlethally injured cells that are dysfunctional can die or can subsequently recover function and structure
(pathway 2). Growth factors are likely to play a role in the proliferative response along pathway 1, and possibly in the recovery of nonlethally
injured cells (pathway 2).
phospholipids followed by rapid proliferation of tubular epithe-
hal cells on the second day of the syndrome [13—15]. These
observations indicate that anabolic mechanisms overcome the
unfavorable effects of systemic catabolism and the azotemic
environment that ordinarily inhibit cell growth. Previous stud-
ies in our laboratory showed that in rats with nephrotoxic acute
renal failure, infused amino acids acted directly on regenerating
renal cells to stimulate synthesis of phosphatidylcholine and
protein, essential for the biogenesis of organdies and surface
structures required for normal cell function [16]. We also
observed improvement in renal function [17]. Extrapolation of
these results suggests that in patients with acute renal failure,
amino acids delivered after the injury could act directly on renal
cells to speed recovery of structure and function. Provision of
nutrients and effective dialysis also might promote regeneration
by facilitating the action of growth factors released by surviving
renal cells in the injured nephron.
Cell biology of renal growth factors
Growth factors produced in the kidney could have initiated
cell proliferation and the tufts of tubular cells observed in the
patient presented, who died of mercuric-chloride-induced tubu-
lar necrosis (Fig. 1). Growth factors are polypeptide messen-
gers that can stimulate dormant cells in the G0 phase of the cell
cycle to initiate DNA synthesis and subsequently to undergo
mitosis. Growth factors affect target cells by binding to specific
surface receptors. This ligand-receptor interaction results in
activation of an intracellular effector mechanism, such as the
tyrosine kinase domain of the receptor or the phosphatidyhino-
sitol signaling pathway [18, 191. Signal transduction is followed
by a cascade of biochemical events that initiate DNA synthesis.
Recent work in many laboratories has identified the amino acid
sequence of growth factors and the nucleotide sequence of the
genes that encode them [10]. Growth factors are derived from
larger precursor molecules by proteolytic processing (Table 1).
Epidermal growth factor (EGF) and insulin-like growth factors
(IGFs) act on renal cells to stimulate exit from the premitotic or
resting (G0!G1) phase of the cell cycle, whereas transforming
growth factor-type /3 (TGF-f3) impedes the exit of renal cells
from G1. These observations, and the low mitotic index (0.1%)





hTGF-/3l 390 112 2.5
mTGF-/32 414 112 2.4
hEGF 1207 53 5.0
hTGF-a 160 50 4.8
hIGF-I 156 70 9.0, 5.3, 7.7
hIGF-Il 180 67 4.9, 6,Oe
hPDGF-A 211 125 1.9, 2.3, 2.8
hPDGF-B 240 160 4.2
haFGF 155 140 4.8
hbFGF 155 146 2.2, 4.6
a Adapted from Ref. 10b Source of growth factor: h, human; m, monkey; TGF, transforming
growth factor; EGF, epidermal growth factor; IGF, insulin-like growth
factor; PDGF, platelet-derived growth factor; aFGF, acidic fibroblast
growth factor; bFGF, basic fibroblast growth factor
Values are number of amino acidsd Values are number of kilobases
e Values are for adult renal tissue; sizes differ in fetal kidney and
other tissues
of renal cells in vivo [20], suggest that growth inhibitory factors
predominate under physiologic conditions, although the set
point could be shifted when regeneration after injury is re-
quired.
Figure 3 illustrates four mechanisms whereby cell-cell com-
munication can be mediated by peptide messengers. Endocrine
signaling occurs when a protein is secreted into blood or lymph
for transport to distant cell target sites, as is the case with
erythropoietin. A paracrine signaling cell secretes proteins that
affect only adjacent target cells that have functional growth
factor receptors on their surface. In autocrine signaling, cells
respond to protein factors that they release; cells that utilize
this mechanism thus secrete the growth factor and express
receptors for it on their plasma membrane [21]. A juxtacrine
mechanism recently has been described for TGF-a in which the
growth factor domain of the plasma-membrane-bound precur-
sor molecule acts as a ligand for a receptor on an adjacent target
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Fig. 3. Mechanisms of cell-cell communication by growth factors. Cells synthesize precursor molecules (depicted in the cytosol) that can be
processed and released to act as growth factors on cells that produced them (autocrine), neighboring (paracrine), or distant cells (endocrine). Also,
the precursor can be incorporated into the plasma membrane and act on adjacent cells (juxtacrine). The thickened curved and angular regions of
the plasma membrane indicate receptor sites for growth-promoting and growth-inhibitory molecules, respectively. (•, stimulatory growth factors;
A, inhibitory growth factors; w• and ''A, precursor molecules.)
cell that is thereby stimulated to enter mitosis [22]. Consider-
ation of the juxtacrine mechanism could provide fresh insight
into the as-yet-unknown role of the large amount of preproEGF
protein present in the distal nephron of the murine kidney [23].
Receptor number, affinity, biosynthesis and recycling, and the
integrity of signal transduction mechanisms at the level of the
plasma membrane, cytosol, cytoskeleton, and nucleus also are
critical determinants of how cells respond to growth factors.
These molecules could have physiologic effects that are unre-
lated to their mitogenic properties.
Unexpected observations from our laboratory led us to
conclude that renal epithelial cells release growth factors in
response to physiologic signals [24, 25]. Cultures of nontrans-
formed renal epithelial cells derived from the African green
monkey (Cercopithecus aethiops) BSC-l line [261 have been
used, because this simple culture system circumvents many of
the problems inherent in studies of organ growth in a tissue as
complex as the kidney. High-density, quiescent cultures have
been employed to simulate the low proliferative activity of
highly differentiated kidney cells in vivo [27, 28]. Under these
conditions, the epithelial monolayer forms small domes overly-
ing accumulated fluid; the cells thus might have the capacity for
transepithelial transport [29]. The nephron segment from which
BSC-l cells originated is unknown, although their responsive-
ness to vasopressin [30] suggests a relationship to the distal
nephron.
Our studies show that small reductions in the extracellular
potassium or sodium concentrations induce DNA synthesis and
cell multiplication [31, 32], that adenosine diphosphate (ADP) is
the most powerful mitogen yet defined for BSC-1 cells [33], and
that a cytokine of mesangial cell origin, interleukin-1f3, also
promotes growth [34]. These four diverse mitogenic signals,
that is, changes in the extracellular concentration of two
cations, a nucleotide, and a cytokine, also have in common the
ability to induce production of autocrine or paracrine growth
factors by these renal cells (Fig. 4).
Lowering extracellular potassium concentration stimulates
growth of renal cells by an autocrine mechanism. More than 50
years ago, Schrader et al found that systemic potassium deple-
tion, achieved experimentally by feeding rats a diet deficient in
potassium, induced renal growth [35]. Sustained mild hypokale-
mia in rats is associated with a doubling of renal mass due to
both hyperplasia and hypertrophy [36, 37]. An in vitro model of
this phenomenon became available when we found that simply
lowering the extracellular potassium concentration from 5.4
mM (control) to 3.2 mM in confluent cultures of BSC-l cells
induced accelerated growth [31]. Thus, these cells perceive a
reduction in the extracellular potassium concentration as a
mitogenic signal.
We then tested the hypothesis that proliferation in response
to low-potassium medium is mediated by the release of a
growth-promoting factor from the cells [38]. Low-potassium or
control medium was conditioned by placing it on confluent
cultures of BSC- 1 cells. The low-potassium-conditioned me-
dium was aspirated from the dish, and its potassium concentra-
tion was restored to the control value (5.4 mM) by the addition
of potassium chloride. This normal-potassium-conditioned me-
dium stimulated growth of fresh cultures of cells to the same
extent as did unconditioned, low-potassium medium. Growth-
stimulating activity in low-potassium conditioned medium first
appeared after one hour (Fig. 4) and was optimal when the
potassium concentration during conditioning was 3,2 mM. The
growth factor(s) have an apparent Mr of 12,000—30,000, as
determined by ultrafiltration and dialysis. The factor(s) are
highly potent because they retain their stimulatory activity at
dilutions greater than 1:1000. Their activity is destroyed by
heating to 56°C for 30 minutes, but is stable at 4°C for at least 3
ENDOCRINE PARACRINE AUTOCRINE JUXTACRINE
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Fig. 4. Production of autocrine and paracrine growth-promoting factors by renal epithelial cells exposed to low-potassium medium, low-sodium
medium, adenosine diphosphate, or interleukin-1. Left panel: Appearance of growth-stimulating activity in low-potassium medium. BSC-l cells
were exposed to medium containing 3.2 mM K and 0.01% calf serum for different amounts of time. The conditioned medium was collected, and
its K concentration was adjusted to the control value (5.4 mM) by the addition of KCI. This low-potassium-conditioned medium was added to a
fresh culture, and its effect on multiplication was assessed by counting the number of cells 3 days later. Release of growth-stimulating activity was
maximal after one hour of exposure of cells to low-potassium medium. Center-left panel: Appearance of growth-promoting activity in low-sodium
medium. At time zero, confluent cultures were exposed to low-sodium medium (130 mM) containining 0,01% serum, and the conditioned medium
was collected at the times specified on the abscissa. After the Na concentration of the conditioned medium was adjusted to the control value (155
mM) by the addition of NaCI, the medium was added to a fresh culture, and its effect on multiplication was assessed by counting the number of
cells 4 days later. Maximal release of growth-promoting activity was detected by 3 minutes. Center-right panel: ADP stimulates release of PDGF-B
chain. BSC-1 cells were exposed to ADP for I or 2 hours. The conditioned medium was collected, ADP in it was removed by dialysis, and
mitogenic activity was assayed in cultures of normal rat kidney (NRK) fibroblasts. Human anti-PDGF IgG inhibited the capacity of
ADP-conditioned medium to stimulate [3H]thymidine incorporation into DNA. After 1 hour of exposure to ADP, PDGF-like activity was about
10-fold greater than that in control conditioned medium. Right pane!: Interleukin- I/I induces expression of the gro1MGSA gene, whose product is
a mitogen. BSC-l cells were exposed to interleukin-lj3 for different amounts of time. Total RNA was extracted, electrophoresed on a
formaldehyde/agarose gel, transferred to a GeneScreen Plus membrane, and hybridized with a [32P]labeled probe prepared from the A2/gro clone.
The gene for gro/MGSA was maximally expressed at 3 hours. (The data presented are adapted from references 32, 34 38, 50.)
days. This activity differs from that of other, previously de-
scribed growth factors. The growth-promoting activity in low-
potassium-conditioned medium can be antagonized by the
addition of purified TGF-j32, the autocrine inhibitor of BSC- 1
cell growth [39].
This study indicated that stimulation of renal epithelial cell
growth induced by lowering the extracellular potassium con-
centration is associated with the appearance of one or more
mitogenic factors in the medium. This observation provided the
first evidence that cell growth induced by an alteration in the ion
concentration of the extracellular fluid could be mediated by an
autocrine mechanism. It remains to be determined whether
these growth factors are produced by renal cells in animals
rendered hypokalemic by a potassium-deficient diet. In vivo,
the factors could recruit unstimulated cells along the nephron to
replicate, maintain the mitogenic signal, and/or serve an as-yet-
undefined purpose related to cell transport.
Reduced extra cellular sodium concentration induces renal
cell growth and production of growth factors. The influx of
sodium ions is augmented during the onset of proliferation in
mammalian cells [40, 41J, so one might expect to find that
exposure of BSC-l cells to medium containing a reduced
concentration of sodium would inhibit mitogenesis. We were
surprised, therefore, to find that cell multiplication was stimu-
lated when the sodium concentration of the medium was
reduced from 155 mM (control) to 130 mM [32]. The capacity of
low-sodium medium to increase cell proliferation depended on
the decreased sodium concentration, as growth stimulation was
equivalent whether equimolar amounts of choline chloride or
isosmolar amounts of sucrose were used to replace sodium
chloride deleted from the medium.
After exposure of confluent cultures for only 3 to 5 minutes to
low-sodium medium (130 mM) (Fig. 4), the cells release two
growth-stimulatory factors (apparent Mr 6200 and 9000). Re-
lease does not depend on new protein synthesis, as it occurs in
the presence of cycloheximide. The activity in conditioned
medium is stable at 56°C for 30 minutes and is retained after
freezing for many weeks. Treatment with trypsin abolishes the
growth-promoting effect, whereas dithiothreitol does not; these
observations suggest that the low-sodium growth factors prob-
ably are proteins that have no accessible disulfide bonds re-
quired for activity. The growth response to a reduction in
extracellular sodium concentration appears to be cell-type
specific, because low-sodium medium does not stimulate pro-
liferation of fibroblasts. Release of growth factor activity is also
cell-type specific, as conditioned medium from fibroblasts ex-
posed to a reduced extracellular sodium concentration does not
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factors appear chemically and functionally different from other
growth factors. Margaret Walsh-Reitz and Naga Aithal in my
laboratory have purified the 6200 Mr low-sodium growth factor
by reversed-phase high-performance liquid chromatography.
Although its amino acid sequence has not yet been determined,
amino acid compositional analysis indicates that it differs from
known growth factors of similar size.
Low-potassium and low-sodium growth factors. The obser-
vations I have summarized indicate that exposure of renal
epithelial cells to low-potassium or low-sodium medium results
in the rapid appearance of growth-promoting factors in the
extracellular fluid. These autocrine products appear to differ in
that (1) the apparent Mr of the growth factor(s) in low-potassium
conditioned medium is 12,000—30,000, whereas the Mr in low-
sodium conditioned medium is 6,200 and 9,000; (2) the low-
potassium factors first appear in the medium after 60 minutes,
whereas the low-sodium factors are detected as early as 3
minutes; and (3) the growth-stimulating effect of low-potassium
conditioned medium is destroyed by heating at 56°C for 30
minutes, whereas the low-sodium activity is stable under these
conditions.
Identification of the low-sodium growth factor and the obser-
vation that lowering the potassium concentration of medium
from 5.4 to 3.2 mM for one hour releases a growth-promoting
activity suggest that brief alterations in the ionic environment
cause renal epithelial cells and/or their extracellular matrix to
release autocrine products. The liberation of active factors by
renal epithelial cell cultures suggests that renal tissue will
respond similarly in vivo. As alterations in the serum concen-
tration of sodium and/or potassium are common in acute renal
failure, it is tempting to speculate that these derangements in
the extracellular cation concentration could signal intact, non-
lethally injured, and regenerating cells to release autocrine
growth factors that could speed the recovery process.
These observations also suggest that modest reductions in the
extracellular concentration of potassium and sodium might
result in the rapid appearance of physiologic mediators that
could communicate information to other cells along the neph-
ron. These factors might act as messengers between glomerular
and tubular cells in response to changes in peritubular or
luminal ion concentrations. Although the factors released in
response to low-potassium and low-sodium media induce pro-
liferation in cell culture, their physiologic role might be different
in the intact kidney. Many mitogens stimulate fluxes of ions and
nutrients (42—461. One possible role, therefore, could be a
modification of epithelial transport in response to changes in the
extracellular environment. Release of autocrine or paracrine
factors with this property suggests a previously undisclosed
mechanism for regulation of ion and nutrient transport in
adjacent and distant epithelial cells. Additional studies will be
required to determine whether these factors contribute to the
control of renal epithelial cell growth and/or transport in vivo.
AdenOsine diphosphate, a potent mitogen for renal epithelial
cells, stimulates production of paracrine and autocrine growth
factors. During the course of a study to define the role of cAMP
in renal epithelial cell growth, we observed that exogenous
adenosine 5'-monophosphate (AMP), used as a control, was a
powerful mitogen [33]. Each of the adenine nucleotides stimu-
lated DNA synthesis in confluent cultures of BSC-l cells. Both
ADP and AMP were more potent mitogens than ATP, adeno-
Table 2. Effect of ADP on gene expression
Gene Effect of ADP
Egr- 1, NAK1, c-fos, c-myc Expression induced




EGF receptor, /3-actin, y-actin, Constitutive expression unaltered
vimentin, cathepsin L,
thymosin f3
IGF-I, IGF-H, preproEGF, TGF- Genes not expressed or induced
, PDGF receptor, PDGF-A
chain, v-src, v-fms, v-yes
sine, guanine, inosine, and the nucleotides of the latter two
substances. Furthermore, ADP stimulated DNA synthesis
threefold more than any known growth-promoting agent for
BSC- 1 cells. It is important that ADP and AMP were mitogenic
under serum-free conditions, and their stimulatory effect appar-
ently was not mediated by cAMP-dependent mechanisms [33].
In addition, known metabolites such as adenosine, hypoxan-
thine, or inosine did not appear to mediate ADP or AMP
stimulation of DNA synthesis, because they were not as potent
when added to the culture medium. Autoradiography of
[3H]thymidine-labeled cultures indicated that sixfold as many
cells were synthesizing DNA in the presence of AMP than in its
absence. No detachment of cells from the monolayer was
detectable under these conditions. The mitogenic effect of ADP
or AMP did not appear to be mediated through the adenosine
receptor, because the predicted stimulation of DNA synthesis
was observed in the presence of a large excess of theophylline
or 5'-deoxy 5'-methylthioadenosine, which are potent adeno-
sine receptor antagonists. Also, ATP stimulates [3H]thymidine
incorporation in primary cultures of rabbit proximal tubular
cells [47], whereas exogenous adenine nucleotides failed to
stimulate DNA synthesis in fibroblasts [331.
To explore the molecular mechanisms by which ADP exerts
its mitogenic effect, we tested the hypothesis that stimulation of
DNA synthesis in renal epithelial cells of the BSC-l line is
mediated by gene activation. We studied the expression of 26
genes and proto-oncogenes, most of which contribute to growth
control, in BSC-l cells in the absence and presence of ADP
[48—51]. The responses observed were divided into four pat-
terns (Table 2): genes not constitutively expressed, but induced
by ADP; genes whose constitutive expression was increased or
unaltered by the nucleotide; and genes that were neither con-
stitutively expressed nor induced. Exposure of renal epithelial
cells to ADP is followed by rapid elevation of the level of Egr- 1
transcripts at 10 minutes, NAK1 at 20 minutes, c-fos at 30
minutes, c-myc at one hour, maximal expression of c-Ha-ras
mRNA at 12 hours, and stimulation of DNA synthesis between
12 and 24 hours. The level of transcripts for the transferrin
receptor, another cell cycle-dependent gene, is also maximal at
12 hours, whereas expression of the y-actin gene remains
unchanged. Stimulation of Egr-1 by ADP and proto-oncogene
expression occur during the G1 phase of the cell cycle, in that
maximal expression of these transcripts is detected prior to the
increment in DNA synthesis. These findings represent the first
reported examples of increased expression of Egr- 1, NAK 1,
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c-fos, c-myc, c-Ha-ras, and transferrin receptor genes in stim-
ulated, nontransformed epithelial cells. Most important, ADP
activation of gene expression appears to be gene specific.
Genes that are activated rapidly and transiently, and whose
induction is shared by diverse cell types when exposed to
different growth stimuli, are likely to be important in the
transduction of mitogenic signals and regulation of cell prolif-
eration. The Egr-l cDNA sequence encodes a protein with
zinc-finger domains that could facilitate DNA binding [52]. This
protein is postulated to function as a transcriptional regulatory
factor that in turn could control induction of several genes. This
novel gene also is induced in serum-stimulated mouse fibro-
blasts, insulin-stimulated rat hepatoma cells, and phytohemag-
glutinin-stimulated human peripheral blood lymphocytes, thus
sharing many features with c-fos and c-myc [49, 52]. In addition
to increasing the expression of early growth response genes,
ADP also stimulates expression of the gene for TGF-f3, which
encodes a protein that inhibits growth of BSC-l cells, and which
stimulates expression of the genes that encode fibronectin and
tenascin, proteins found in the extracellular matrix (ECM). In
summary, ADP can mimic the action of a growth factor and can
stimulate expression of cell-cycle-specific genes (Egr- 1 and
proto-oncogenes), as well as the gene for TGF-f3, the expres-
sion of which could serve to limit cell proliferation by producing
a negative autocrine growth factor.
During the study of ADP-induced gene expression, we found
that quiescent BSC-l cells constitutively release platelet-de-
rived growth factor (PDGF)-like activity [50]. The presence of a
PDGF-like protein was unexpected because expression of
PDGF was thought to be confined to cells of mesodermal origin
such as fibroblasts and smooth muscle cells [53]. This growth
factor, released from platelets and macrophages during clotting
and wound healing, is a mitogen for cells of mesenchymal
origin, a chemoattractant for smooth muscle cells and mono-
cytes, and a promoter of collagen, proteoglycan, and elastic
fiber protein synthesis [54]. A dimeric glycoprotein of Mr 30,000
comprised of A and/or B chains linked by disulfide bonds [53],
PDGF is most commonly found as a heterodimer (AB), al-
though biologically active homodimers (AA and BB) are
known. The amino acid sequence of the B chain is nearly
identical to the putative transforming protein of the simian
sarcoma virus, which is encoded by the v-sis oncogene; the
cellular homologue is termed c-sis [55, 56]. Three classes of
PDGF receptors have been defined, each of which comprises
two subunits located in the plasma membrane [57, 58]. The a
and 13 receptor subunits are brought together by the presence of
one of the three isoforms of PDGF to form the mature receptor
dimer. The receptor a-subunit can bind PDGF-A chain or
PDGF-B chain homodimers, whereas the /3-subunit can bind
only PDGF-B chains.
Conditioned medium from quiescent BSC-l cells was assayed
for its mitogenic activity on normal rat kidney (NRK) fibro-
blasts, and its chemoattractant activity was assessed on bovine
aortic smooth muscle cells [50]. Both activities were found, and
both could be blocked by human anti-PDGF IgG. The gene for
the B chain of PDGF (c-sis) was constitutively expressed in
these cells, whereas no PDGF A-chain mRNA was detected.
Thus the cells appear to synthesize and secrete a PDGF-like
protein that is a BB homodimer. In this system, ADP increased
by threefold the amounts of PDGF B-chain mRNA and secreted
immunoreactive PDGF-like protein. Most important, ADP rap-
idly induced release of PDGF-like activity, so that one hour
after exposure of the cells to the nucleotide, the amount of
growth factor was increased by more than tenfold (Fig. 4). The
BSC-1 cells did not exhibit a mitogenic response to authentic
PDGF, nor did they express the gene encoding the PDGF
receptor. These results imply that if the PDGF-like protein is
released by renal epithelial cells in vivo, the protein could, via
a paracrine mechanism, initiate proliferation of adjacent stro-
mal (fibroblastic) and/or vascular (smooth muscle) cells within
the organ.
Some transformed cells can release PDGF-like proteins and
express PDGF receptors [59, 60]. These findings suggest that an
autocrine mechanism contributes to their proliferation. Human
fetal kidney and Wilms' tumor cells have been shown to
produce PDGF [611; production of the growth factor by Wilms'
tumor cells may be a marker for their embryonic ongin rather
than the malignant phenotype. Like the BSC-l line, cells
derived from Wilms' tumor and fetal kidney bind little PDGF;
this finding suggests that PDGF might have a paracrine function
in vivo.
Figure 5 summarizes some of the mechanisms by which ADP
can initiate growth of renal epithelial cells. As Table 2 shows,
ADP is presumed to bind to a specific plasma membrane
receptor and to activate the early response genes Egr- 1, NAK 1,
c-fos, and c-myc. There is rapid release of PDGF B-chain
homodimer, a paracrine factor; TGF-f32, an autocnne growth
inhibitor; and an apparently novel autocrine growth stimulator
identified by Sreedharan Kartha in our laboratory. Further,
ADP also activates the proto-oncogenes c-sis and c-Ha-ras as
well as genes encoding growth factors. Thus ADP induces
release of paracrine, and positive and negative autocrine,
growth factors. These observations provide evidence that a
single type of renal epithelial cell can generate diverse physio-
logic messengers in response to one signal. The capacity of
infused adenine nucleotides to enhance recovery from nephro-
toxic, ischemic, and obstructive renal injury might be mediated
in part by the capacity of the nucleotide to initiate mitogenesis
and release a variety of growth factors [33, 48—51].
Interleukin-1 /3 stimulates cell growth and induces expression
of gro/MGSA. Interleukin- 1, a protein released by mesangial
cells, macrophages, and monocytes, has diverse biologic effects
[62, 631. It stimulates proliferation of mesangial cells, lympho-
cytes, fibroblasts, and glioblastoma cells, inhibits the growth of
certain tumor cells in vitro, and contributes to the immune
response, inflammation, and hematopoiesis. This cytokine also
stimulates DNA synthesis in BSC-1 cells [34]. Interleukin-1j3
rapidly induces expression of the gro/MGSA gene (Fig. 4),
whereas two other mitogens, ADP and serum, do not. The
gro/MGSA gene product has diverse growth-regulatory activi-
ties and has been identified in three different settings: as the gro
gene, which is expressed in tumorigenic but not nontumongenic
hamster fibroblasts [64]; as MGSA, the melanocyte growth-
stimulating activity secreted by melanoma cells in culture [65];
and as the KC gene product, which is expressed rapidly in
PDGF-stimulated fibroblasts [66]. A recent study in our labo-
ratory showed that purified MGSA initiates DNA synthesis in
quiescent cultures of BSC-l cells (unpublished results). These
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Fig. 5. Summary of growth-regulatory events in BSC-I cells following exposure to ADP. The ADP binds to the plasma membrane (PM) and
subsequently acts in the nucleus (N) to stimulate the expression of genes that encode growth-stimulatory and -inhibitory factors, as well as
transcriptional regulators. The ADP also stimulates rapid release (broken line) of growth factors such as PDGF-like protein, TGF-13, and a novel
autocrine growth stimulator, an ADP growth factor (ADP GF).
factor interleukin- 1 p [63] induces renal epithelial cells to ex-
press the gene for MGSA, which encodes a protein that is also
an autocrine growth factor.
Growth factors as possible therapy in acute renal failure
Growth factors identified in renal tissue that could contribute
to regeneration after acute renal failure via autocrine, para-
crine, or juxtacrine mechanisms are described in Table 3.
Administration of purified growth factors as pharmacologic
agents alone or in combination eventually might prove useful in
treating patients with this condition.
Epidermal growth factor. A potent renal epithelial cell mito-
gen, EGF is a single-chain peptide of 53 amino acids cross-
linked by 3 disulfide bonds [67]. The preproEGF mRNA in
murine kidney is translated to preproEGF. The function of
renal preproEGF is not known, but intracellular processing to
the mature growth factor apparently does not occur [23].
Urinary EGF might be derived by proteolytic cleavage of the
preproEGF protein localized in the plasma membrane. In the
mouse kidney, preproEGF mRNA is found in the distal neph-
ron and loop of Henle [23], but we were unable to detect the
mRNA by in situ hybridization in normal human renal tissue
(unpublished observations). The EGF receptor is found in the
basolateral membrane of the proximal tubule and collecting
duct, and to a lesser extent in distal tubules and glomeruli of
rabbit nephrons [68]. The EGF membrane receptor protein
likely represents the cellular analogue of the protein product of
the viral erb-B oncogene [69]. In BSC-l cells, the number of
EGF receptors is approximately tenfold higher in sparse cul-
tures than at high cell density, although receptor affinity appar-
ently does not change [70]. In vivo, a renal insult could unmask
EGF receptors on injured or intact renal cells when adjacent
cells detach from the tubular basement membrane. Presumably
these surviving cells would be more responsive to the mitogenic
effect of EGF produced at the site of injury. Following cell
proliferation and reepithelialization of the nephron, the recep-
tors again would be down-regulated.
The role of EGF in regeneration after acute renal injury and
as a pharmacologic agent has been investigated recently. The
renal synthesis of EGF falls rapidly after acute ischemic injury
in the rat; expression of preproEGF mRNA is reduced by 60%
at 2 hours and is undetectable by 24 hours, by which time
urinary excretion of EGF protein has declined by 97% [711. In
contrast, expression of the early response genes (c-fox, Egr-l
and c-myc) increases. It is important that binding of [125j] EGF
increased 3.6-fold in renal cortical tissue and 2.5-fold in the
medulla 24 hours after injury [71]. In a cis-platin model of acute
tubular injury, decreased preproEGF mRNA expression was
found in cells of the distal convoluted tubule and thick ascend-
ing limb of Henle's loop 12 to 72 hours after injury, whereas
salivary gland preproEGF mRNA expression was unaffected
[72]. Thus acute tubular injury initiates a specific decline in
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Table 3. Growth factors that possibly participate in renal regeneration
Factor Site of production





































































Speeds recovery of ARF in rats
Binds to EGF receptor
Hyperplastic response becomes
hypertrophic
Increases mRNA synthesis after
uninephrectomy
Increases protein and mRNA
synthesis in early DM in rats
Embedded in ECM




Isolated from BSC- I
conditioned medium
renal EGF gene expression, whereas surviving cells exhibit
increased affinity for the growth factor.
Three recent publications provide strong evidence that phar-
macologic administration of EGF accelerates recovery from
experimental acute renal injury in the rat. An 8-day intrarenal
infusion of EGF, or a single subcutaneous injection of the
growth factor, each dampened the rise in serum creatinine
following hypoxic renal injury and stimulated [3H] thymidine
incorporation into DNA in renal tubular cells 24 hours after the
insult [73, 74]. A similar augmentation of the repair process
following subcutaneous administration of EGF was demon-
strated in a model of mercuric-chloride-induced acute renal
failure [75]. Histologic examination showed that EGF treatment
did not alter the extent of tubular necrosis at 24 hours. Thus, in
three different models of acute tubular injury, EGF given soon
after a hypoxic or nephrotoxic insult enhanced regeneration of
renal epithelial cells and recovery of glomerular filtration.
Transforming growth factor-n. A 50-amino acid polypeptide,
TGF-a exerts its biologic effects by binding to the EGF receptor
[221. Recent evidence that the precursor form of TGF-a is
biologically active suggests that both the processed soluble and
membrane-bound precursor forms of the growth factor might be
mitogens, by autocrine and juxtacnne mechanisms respectively
(Fig. 3). Because TGF-a protein is secreted by developing
mouse mesonephric tubules, the major physiologic role of the
growth factor is thought to be in embryonic development [76].
Renal carcinomas and other human tumors produce TGF-a,
which sometimes can be recovered from the urine of these
patients [76]. The growth factor is not produced by renal
epithelial cells of the BSC-l line (unpublished observations),
although a small amount of mRNA for this growth factor is
detected in normal adult kidney [77]. The role of TGF-a in renal
repair after injury has not been defined. Because this growth




IGF-I Medullary collecting duct—rat
IGF-H Throughout kidney, 100 times more
in fetal kidney





U Abbreviations: All, angiotension II; ARF, acute renal failure; DM, diabetes mellitus; ECM, extracellular matrix; GFR, glomerular filtration
rate; GF, growth factor; IL, interleukin; JG, juxtaglomerular; PLC, phospholipase C; PCT, proximal convoluted tubule; RBF, renal blood flow;
SMC, smooth muscle cells.
IL-i mRNA in BSC-l cells
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TGF-t would be as effective as EGF in hastening recovery from
acute tubular necrosis.
Transforming growth factor-$. The autocrine release of
growth-inhibitory activity was first inferred by Holley and
coworkers in 1978 from observations made on crowded cultures
of BSC-l cells [78]. They noted stimulation of [3H] thymidine
incorporation into DNA when conditioned medium containing
serum was aspirated and replaced by fresh, serum-free medium.
As no serum growth factors were added to the cells, it appeared
that DNA synthesis was initiated by removal of a cell-derived
growth inhibitor. Subsequent purification of the inhibitor pro-
tein indicated that it could arrest sparse cultures of growing
cells in the G1 phase of the cell cycle, but proliferation resumed
when the protein was removed [79]. This reversible effect on
cell growth, and the low concentration required for inhibition,
suggested a physiologic role for the inhibitor in the control of
proliferation. The growth-inhibitory effect could be overcome
by the addition of EGF to the culture medium; therefore,
proliferation of renal cells in culture can be regulated by factors
with opposing effects [80]. In 1984, the growth inhibitor was
reported to be biologically and chemically similar to TGF-13
[81]. The complete amino acid sequence of the BSC-l cell
growth inhibitor, determined from the nucleotide sequence of
the cDNA, has been shown to correspond to TGF-132 [39].
Human TGF-/31 is a polypeptide with an apparent Mr of 25,000,
composed of two chains linked by disulfide bonds. There is 71%
identity between the amino acid sequences of monkey TGF-/32
and human TGF-/31 [82], closely related proteins with similar
properties.
In most cells, TGF-f3 mRNA is constitutively expressed,
although production of the protein as detected by immunohis-
tochemistry appears limited in the adult mouse to cortical distal
tubular cells, and in bovine kidney to collecting duct [83, 84]. In
renal epithelial cells in culture, TGF-/3 inhibits [3H] thymidine
incorporation, whereas it stimulates growth of fibroblast colo-
nies in soft agar [81]. In primary cultures of rabbit proximal
tubular cells, TGF-/32 can convert the mitogenic effect usually
exerted by insulin and hydrocortisone into a hypertrophic one;
this finding suggests a role for the factor in compensatory renal
growth after uninephrectomy [85]. Also, TGF-/3 induces syn-
thesis of fibronectin and its incorporation into ECM by lung
epithelial cells and fibroblasts in culture [86]. In a rat model of
wound healing, TGF-p2 increased synthesis of type-I procolla-
gen by fibroblasts, and hastened the rate of healing [87]. An
antiserum to TGF-f3l appears to be efficacious in the treatment
of a murine model of mesangial proliferative glomerulonephritis
[88]; this growth factor therefore might play a critical role in the
accumulation of basement membrane components in specific
glomerulonephritides.
Insulin-like growth factors. The IGFs, also termed so-
matomedins, are peptide growth factors that were first isolated
from human plasma fractions. The IGFs share the following
biologic activities: insulin-like activity on glucose metabolism,
stimulation of sulfate incorporation into cartilage, and a mito-
genic effect on different cell types [89]. Insulin-like growth
factor-I, also known as somatomedin C, is a basic, single-chain
polypeptide of 70 amino acids with an apparent Mr of 7649 [90].
A slightly acidic peptide of 67 amino acids, IGF-II has an
apparent M of 7471; there is 62% identity between IGF-I and
II, and both have a high degree of homology with human
proinsulin [91].
Two types of IGF receptors have been described [92]. Type-I
receptors bind IGF-I with an equal or greater affinity than
IGF-II and bind insulin with low affinity, whereas type-Il
receptors bind IGF-II with greater affinity than IGF-I and do
not bind insulin. The type-I receptor is structurally homologous
to the insulin receptor, with two disulfide-linked subunits that
bind the peptide, and two subunits that have intrinsic tyrosine
kinase activity. The type-Il receptor is a single polypeptide that
is identical to the mannose 6-phosphate receptor, a membrane
protein that directs proteins to lysosomes [93]. The type-I
receptor likely mediates the mitogenic response to both IGF-I
and II in most systems. The physiologic role for the type-Il
receptor in mediating the tissue response to IGF-II is unknown
[92]. The distribution of IGF receptors has been studied on
proximal tubular cells isolated from canine kidney [94]. Insulin-
like growth factor-I-stimulated phosphorylation of the IGF-I
receptor has been demonstrated only in preparations of baso-
lateral membranes, and not in those from brush border. Insulin-
like growth factor-Il receptors appear to be equally distributed
on basolateral and brush-border membranes.
The site of production of IGF-I was originally considered to
be the liver, from which it is released in response to growth
hormone [89]. However, evidence indicates that IGF-I is pro-
duced by most, if not all tissues, and acts as an autocrine or
paracrine effector [951. Production of IGF-I and its growth-
hormone dependence have been demonstrated in rat kidney as
well as in other rat tissues [96]. Insulin-like growth factor-I
mRNA is also present in adult human kidney, although its
distribution within the organ has not been determined [97]. In
rat kidney, immunoreactive IGF-I is localized primarily in the
medullary collecting duct and is not found in the proximal or
distal tubules [98]. Administration of IGF-I to fasted rats
increases renal plasma flow and GFR while decreasing renal
vascular resistance [99]. Insulin-like growth factor-Il is less
directly under growth hormone control and is believed to be an
important fetal growth factor [100]. Insulin-like growth factor-Il
mRNA is present both in fetal and adult human kidney;
however it is 10- to 100-fold more abundant in the fetal organ.
Increased immunoreactive IGF-I has been demonstrated in
kidneys after ischemic injury [101], and this growth factor can
induce hypertrophy of proximal tubular cells in culture [102].
How IGF-I reaches proximal tubular cells in vivo remains
uncertain, because its site of production is in the terminal
collecting duct. The contribution of IGFs to renal growth and
repair after injury remains to be clarified.
Platelet-derived growth factor. Mesangial cells secrete a
PDGF-like protein and express PDGF receptors [103]. Glomer-
ular endothelial and mesangial cells proliferate in response to
PDGF; the factor thus could play a role in growth responses in
the glomerulus [103]. Although PDGF is not a mitogen for renal
epithelial cells, it could contribute to regeneration after acute
renal failure by attracting infiltrating inflammatory cells and
stimulating adjacent fibroblasts to release factors that are ii-
gands for epithelial cell receptors. In this way PDGF might
coordinate tubular and glomerular proliferation after renal
injury.
Fibroblast growth factors. The FGFs are two closely related
polypeptides with different isoelectric points, designated as
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Fig. 6. Growth regulation in regenerating renal epithelial cells. Cells at the edge of an injured segment of the nephron are shown during early renal
regeneration following acute tubular necrosis. Pictured are non-necrotic cells, a dividing cell, and a migrating squamoid cell. Proliferation may be
mediated in part by synthesis of growth-stimulatory factors, followed by cellular processing and release of the active molecules. Symbols for
growth factors, precursors, and receptors are as in Figure 3.
acidic FGF (aFGF) and basic FGF (bFGF). The cDNA clones
encoding both proteins have been isolated, and the predicted
amino acid sequences indicate 55% structural homology be-
tween these two growth factors [1041. The FGFs are mitogenic
for most, if not all, nonterminally differentiated cells of meso-
dermal or neuroectodermal origin. Also, FGFs are potent
inducers of blood vessel growth. They are chemotactic for
vascular endothelial cells, and they induce expression of plas-
minogen activators and collagenases, proteolytic enzymes that
presumably mediate tissue remodeling.
The FGFs bind to heparan sulfates, the principle molecules of
extracellular matrix in tissues and cell culture [1051. Their
presence in extracellular matrix suggests that they can mediate
proliferation of cells adjacent to the basement membrane. For
example, FGF is not secreted into the medium by endothelial
cells, but FGF does appear to operate following its deposition
into extracellular matrix. In this manner, FGF could be a local
growth regulator and could induce regeneration after denuda-
tion of the overlying cell layer. This property might explain
some of its ability to promote wound healing. It has been
difficult to define the mechanism by which FGF is deposited
into the extracellular matrix, as both aFGF and bFGF lack a
classic leader sequence required for cellular secretion [104,
106]. It is not known whether FGF is released only from
damaged or dying cells, is delivered to sites of injury or
inflammation by stimulated macrophages, or is secreted by an
as-yet-uncharacterized mechanism [106].
Until recently, aFGF was thought to exist only in neural
tissue, but both acidic and basic FGF have been isolated from
bovine kidney [107, 1081. Studies in embryonic kidney suggest
a role for FGF in renal angiogenesis [109]. During embryonic
development, renal differentiation is driven by the interaction of
different types of cells. Contact with the epithelial ureteric bud
induces the nephrogenic mesenchyme to differentiate, which
then leads to stimulation of blood vessel ingrowth. Little work
has assessed the effects of FGF on kidney cells, although aFGF
stimulates proliferation of BSC- 1 cells (unpublished observa-
tions). Whether FGF is present in glomerular or tubular base-
ment membranes or participates in renal cell regeneration after
injury is not clear.
Angiotensin II. Angiotensin converting enzyme (ACE) inhib-
itors block compensatory renal hypertrophy alter partial renal
ablation in rats [110]. Although this observation has been
ascribed to changes in intrarenal hemodynamics, direct cellular
effects of angiotensin II have been defined. Angiotensin II can
induce hypertrophy of smooth muscle cells in culture [111], and
it can stimulate sodium reabsorption both in intact nephrons
and in cultures of proximal tubular cells, possibly via stimulated
Na/H antiporter activity [112, 113]. In mouse proximal tubular
cells of the MCT line, exposure to 10_8 M angiotensin II
increased cell size and protein synthesis; these effects were
blocked specifically by saralasin [114]. In MCT cells pretreated
with EGF, the hypertrophic action of angiotensin II became a
proliferative one. Relatively high doses of amiloride blocked
angiotensin Il-induced protein synthesis and partially abolished
the increase in cell size; thus, increased cell sodium content
might be required for hypertrophy to occur after stimulation
with angiotensin II [114].
Plasma renin activity is increased in humans and animals with
acute renal failure, and elevated intrarenal angiotensin II levels
could contribute to abnormal autoregulation of blood flow in the
recovering kidney [115, 116]. The direct renal cellular effects of
angiotensin II on sodium transport and hypertrophy suggest
that this protein could have physiologic significance during
tubular regeneration after injury.
Conclusions
A major theme of this Forum is that renal cells release
autocrine and paracrine growth factors in response to extracel-
lular signals and could thereby mediate repair of the nephron
after acute renal failure (Fig. 2). Examples of such signals are
reductions in the extracellular potassium and sodium concen-
tration, liberation of adenine nucleotides by injured or dying
cells, and cytokines released by neighboring cells (Fig. 4). As
growth factors alter ion and nutrient transport and other aspects
of cell metabolism, these effector molecules could mediate
repair of biochemical and/or subcellular injuries and thereby
allow an injured cell to recover, and subsequently to respond to
autocrine, paracrine, orjuxtacrine proliferative signals. Epithe-
hal cells at both ends of a necrotic segment of the nephron, and
. .
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other surviving isolated cells along its denuded surface, are
responsible for regenerating the tubular epithelial cell lining
[14]. Proliferation of these cells with subsequent sliding along
the basement membrane permits rapid restitution of the tubule.
Growth factors could stimulate the transition of these cells from
the G0 toG1 phase of the cell cycle (Fig. 6), and possibly speed
protein and phospholipid synthesis for the formation of brush-
border and basolateral membranes. The intact basement mem-
brane plays an important role in the healing process by providing
a structural framework for the proliferating cells. Alterations in the
extracellular matrix and its connections to the cytoskeleton occur
with acute tubular injury and likely result in profound disruption of
cellular function. Because several growth factors stimulate cells to
synthesize and release extracellular matrix components such as
collagens, fibronectin, and tenascin, repair of the damaged base-
ment membrane also might be mediated by molecules of renal cell
origin. At present the factors governing repair of the extracellular
matrix and cytoskeleton following acute tubular injury remain
unknown.
Growth factors delivered to renal epithelial cells from local
and systemic sources and acting through more than one mech-
anism may orchestrate the proliferative repair of the nephron
after cellular necrosis. Both IGF-I and EGF are produced by
renal epithelial cells; factors made by mesangial cells, such as
PDGF and interleukins, also might contribute to tissue repair.
The FGFs, which are found in the extracellular matrix, may be
a stored form of growth factor for surviving cells that becomes
operational after cell necrosis. Transforming growth factor-f3,
which can convert a proliferative signal into a hypertrophic one,
may facilitate development of the nascent cells into a mature
epithelium, and act as a negative feedback signal to limit
proliferation as repair of the nephron nears completion.
Renal growth factors also might act on a population of renal
cells arrested in the G2 phase of the cell cycle. Described by
Pederson and Gelfant in 1970 [117], these cells could be rapidly
induced to divide by paracrine or autocrine factors, thereby
beginning replacement of cells that detached from the tubular
basement membrane. Mesangial, endothelial, and/or infiltrating
inflammatory cells at the site of renal injury represent additional
sources of growth factors that could aid cells of the injured
nephron [118, 1191. Growth factors and possibly adenine nude-
otides released by regenerating and injured renal epithelial cells
also could stimulate fibroblast cell growth. In addition, tubular
and fibroblastic cells may be stimulated by autocrine and/or
paracrine mechanisms to synthesize and secrete extracellular
matrix proteins, which could repair rents in the tubular base-
ment membrane. As I pointed out earlier, it is interesting that
the exuberantly proliferating surviving cells are located in the
region of a disrupted basement membrane (Fig. 1). Although
growth factors may have induced proliferation at this site, they
apparently were unable to accomplish repair of the damaged
basement membrane in this patient.
The National Kidney and Urologic Diseases Advisory Board
1990 Long-Range Plan concluded that acute renal failure is the
most costly kidney condition requiring hospitalization, that the
number of cases has increased recently as a consequence of
complicated surgical procedures in older patients, and that the
mortality rate has not changed since the early 1950s [120, 1211.
Thus, a considerable need exists for new therapeutic ap-
proaches that can speed regeneration and reduce mortality. The
information presented at this Forum provides a rationale for
considering specific growth factors in combination with suffi-
cient nutrients, calories, and dialytic therapy to optimize recov-
ery. An important goal of future research efforts is to identify
new renal growth factors, and then to isolate and prepare them
for use in combination with known factors to speed renal
regeneration and improve the outcome in patients with acute
renal failure.
Questions and answers
DR. JOHN C. LIESKE (Fellow, Section of Nephrology, The
University of Chicago, Chicago, Illinois): Of the growth factors
discussed, only EGF has been demonstrated to alter the course
of acute renal failure when administered systemically after an
insult in experimental animal models. However, intrarenal
levels of EGF mRNA and production of urinary EGF both
decline precipitously during acute renal failure. What is the role
of EGF in recovery after renal injury in vivo?
DR. TOBACK: The points you make argue against local release
of EGF as a key mediator of recovery after acute renal failure.
If autocrine production of EGF plays a role in renal regenera-
tion, one would have to propose it does so by binding to an
increased number of EGF receptors, as has been demonstrated
in rat renal tissue after ischemic injury [711. The experimental
success of pharmacologic doses of EGF in attenuating the
course of acute renal failure in rats appears to be mediated by
the greater number of receptors as well. Another source of EGF
in vivo could be the systemic circulation; the plasma concen-
tration is in the range of 20 pg/mt [671. This relatively low
concentration may achieve physiologic importance in the set-
ting of acute renal failure because the number of EGF receptors
per cell is increased.
The physiologic function of urinary EGF remains undefined,
as does the mechanism by which it enters the urine. Even
though the mRNA that encodes preproEGF is detected in the
thick loop of Henle and distal nephron in mice, and EGF can be
detected immunohistochemically in the apical regions of these
cells, little EGF can be extracted from renal tissue [67]. The
amount of EGF excreted in human urine each day (approxi-
mately 50 zg) is too large to be accounted for by efficient renal
clearance of the growth factor. At present it is thought that
preproEGF is inserted in the luminal plasma membrane, where
it is subsequently cleaved by urinary proteases to release the
mature growth factor [67]. The potential actions of EGF in
distal tubular fluid are a matter of speculation. One possibility is
that EGF stimulates proliferation of epithelial cells to replace
those that have detached or died as a result of the acidic pH and
relatively high concentration of toxic metabolites in the lumen
of the distal nephron, ureters, and bladder.
There could be a practical problem with administering phar-
macologic doses of EGF to patients in an effort to speed
recovery after acute renal failure. TGF-a, which binds to the
EGF receptor, causes calcium resorption from mouse calvaria
in culture, and subcutaneous EGF and TGF-a administered
over a 2-day period to mice induced mild hypercalcemia [122,
123]. The mechanisms of bone resorption and hypercalcemia
remain to be defined, but these might be consequences of the
interaction of EGF with the parathyroid hormone receptor
[124]. Hyperphosphatemia is often found in acute renal failure;
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thus the risk of dystrophic and metastatic calcification subse-
quent to further elevations in the calcium-phosphorus product
after EGF administration ultimately might limit the clinical
utility of the growth factor.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Al-
though not well substantiated for ischemic acute renal failure,
for some models of nephrotoxic acute renal failure, specifically
those induced by heavy metals or glycerol, it appears that the
first insult confers on the kidney resistance to a second expo-
sure to the same insult. Does modern biology offer any insight
into this phenomenon?
DR. TonAcK: The molecular basis for this observation is not
known. Animals recovering from certain types of acute renal
failure often are resistant to a second exposure to the same
agent, for example, glycerol, uranium, or gentamicin [125]. This
is not the case in animals subjected to ischemic renal injury;
they are more susceptible to acute renal failure following an
additional ischemic insult. Some agents confer resistance to a
different nephrotoxin, whereas others do not. For example,
glycerol-induced injury protects against exposure to mercuric
chloride, but mercuric chloride does not protect against treat-
ment with gentamicin.
Several factors may play a role in this phenomenon. There
appears to be decreased sensitivity of mesangial cells to angio-
tensin II in glycerol-induced acute renal failure. This could
blunt angiotensin-mediated mesangial contraction and possibly
minimize the expected decline in glomerular filtration that
would follow a second dose of glycerol [125]. In uranium-
poisoned dogs, repopulation of degenerated tubules is accom-
plished by recovery of injured cells, mitosis, and ingrowth of
tubular cells at the wound margin [126]. In this model, it is the
migrating new cells that appear resistant to injury by a second
exposure to uranium. Resistance of these regenerating cells
might be a consequence of their decreased capacity to take up
and concentrate the nephrotoxin. A solute diuresis in this
setting could have a salutary effect by preventing accumulation
of nephrotoxins in the kidney, and/or by relieving tubular
obstruction by casts of necrotic cells.
Along the lines discussed today, one could hypothesize that
local production of growth factors occurs during the initial renal
insult to facilitate recovery of injured cells and to stimulate
mitogenesis to replace necrotic ones. A second exposure to the
nephrotoxin might rapidly trigger synthesis and release of the
same factors and result in the brisk repair of the tubular lesion;
this repair would be interpreted as relative resistance to the
second insult. Perhaps in this instance renal cells act like cells
of the immune system when confronted with an antigen that
was encountered previously; they exhibit an anamnestic re-
sponse.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I have two ques-
tions: First, do the low-potassium and the low-sodium growth
factors stimulate renal cell growth only, or do they make cells in
other organs of the body grow at a comparable rate? My second
question refers to the work of Jean Oliver. As I recall, Oliver
distinguished between simple cell death and what he called
tubulorrhexis, that is, destruction of the basement membrane.
Does that old distinction have any relevance today?
DR. TOBACK: The data we have about the low-sodium and
low-potassium growth factors is that neither of them stimulate
the growth of fibroblasts. Given that very limited information,
they appear relatively specific as mitogens for renal epithelial
cells, but that's the extent of our knowledge at the moment.
As to Jean Oliver's work, it is of interest that the most
marked accumulation of cells noted in the microdissected
nephron from the patient described today (Fig. I) occurs in a
region of the tubule that exhibits tubulorrhexis; these prolifer-
ating cells overlie a disrupted portion of the basement mem-
brane. We know from our work using ADP as a mitogen, and
from studies by others, that as cells proliferate they express the
genes that encode and secrete extracellular matrix proteins
such as collagen, fibronectin, and laminin [127]. Incorporation
of these proteins into the tubular basement membrane could
facilitate its repair after injury. If the patient with acute renal
failure that we are discussing here had been hospitalized today,
she would have received nutritional and hemodialysis support.
This treatment might have provided sufficient time for these
proliferating cells to have secreted enough extracellular matrix
material to repair the damaged tubular basement membrane
(Fig. 1), and to have allowed eventual return of her renal
function. In the rat, it appears that an intact tubular basement
membrane provides a scaffold on which regenerating epithelial
cells migrate [2, 4, 5]. The cells move from both ends of the
damaged segment of the tubule until they meet and reepithe-
lialize the nephron. Intact, embryonic rest or "stem" cells that
survived the renal injury also can proliferate, migrate, and
contribute to the repair process. The presence of acidic and
basic FGF in the extracellular matrix [128] may serve as an
available reservoir of growth factors that could initiate repair
and proliferation of cells after injury, prior to the synthesis and
secretion of new molecules for this purpose.
DR. LIESKE: Evidence is increasing that alterations in the
cytoskeleton of renal cells might be responsible for functional
abnormalities in the nephron after acute injury. Is there any
evidence that growth factors play a role in the formation or
repair of the cytoskeleton?
DR. TOBACK: Connections between the extracellular matrix
and the cytoskeleton appear to be important in embryogenesis
and during morphologic differentiation of the renal epithelium.
Enzymes, receptors, and carriers show an asymmetric distri-
bution between the apical and basolateral surfaces of polarized
epithelial cells, and the lipid content and physical properties of
these two plasma membrane domains show distinct differences
[9]. The establishment of asymmetry initially might involve
cell-cell contacts via surface glycoproteins called cell-adhesion
molecules, such as uvomorulin. Also important in the develop-
ment of cell polarity are contacts between the cell and the
extracellular matrix. Cellular receptors for the extracellular
matrix molecules laminin, collagen, and fibronectin belong to
the integrin supergene family [129]. Laminin is secreted into the
basement membrane of cells destined to become renal epithe-
hum [130]. The gene encoding the A chain of laminin is
constitutively expressed, whereas expression of B chain mRNA
precedes commitment to an epithelial cell morphology in organ
culture [1311. Furthermore, antibodies to the A chain can
prevent development of polarity in these cells. Production of
type-IV collagen also appears to be linked to development of
renal epithelial cell polarity, as undifferentiated mesenchyme
produces only type-I and -III collagen [132]. Syndecan, a
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cell-surface proteoglycan, behaves as an ECM receptor. It
associates intracellularly with actin and is localized to the
basolateral surface of epithelial cells [133]. The extracellular
domain of the syndecan molecule contains heparan sulfate
chains, which can reversibly bind bFGF. Mammary epithelial
cells made syndecan-deficient with antisense cDNA lose epi-
thelial polarity and assume a fibroblastic morphology.
Changes in the organization of cytoskeletal actin filaments
represent early evidence of polarity in renal epithelial MDCK
cells in culture. Progressive organization of the actin network,
from the apical and basolateral surfaces, accompanies develop-
ment of polarity in these cells during the first 12 hours in culture
[9]. Microtubules also appear to organize sequentially over five
days. If formation of cell-cell contacts between MDCK cells in
culture is prevented by incubation in low-Ca medium, the
polarized distribution of certain plasma membrane proteins is
prevented [134]. Alternatively, other proteins still distribute
normally if adhesion is prevented with low-Cat medium, but
not if formation of actin microfilaments is disrupted with
cytochalasin D [135]. Thus more than one mechanism of
localization of cellular proteins to specific regions of the plasma
membrane exists,
Alterations in cytoskeletal components can result from renal
injuries not severe enough to cause cell death. Permeability of
tight junctions, as measured by ruthenium red penetration of
microperfused tubules, increases in a stepwise manner after 5,
15, and 30 minutes of ischemia [136]. This phenomenon
is accompanied by the abnormal redistribution of Na-K
ATPase from the basolateral into the apical membrane, indicat-
ing loss of so-called "fence" function mediated by tight junc-
tions that separate apical and basolateral membrane domains.
Other changes of the cytoskeleton with ischemia include loss of
brush-border terminal-web actin filaments after 15 minutes and
diffuse redistribution of actin throughout the cytoplasm after 50
minutes [137]. Disrupting microfilaments of perfused tubules
with cytochalasin D decreases their capacity for sodium reab-
sorption [137]; this finding suggests that morphologic alterations
of the cytoskeleton after ischemia correlate with functional
derangements of the nephron.
Changes in renal epithelial cell pH are associated with
mitogenesis, cytoskeletal alterations, and modified receptor
number. Renal mass increases in rats made chronically acidotic
by ammonium chloride administration [138], and acidification of
the culture medium is associated with mitogenesis of primary
cultures of mouse renal tubular cells, an effect not observed in
hepatocytes or fibroblasts [139]. Stimulation of growth with
acidosis is preceded by an increase in intracellular sodium,
possibly mediated by the Na-H antiporter [139]. Acidifica-
tion of porcine kidney cells in culture decreases the lateral
mobility of vasopressin V2 receptors while increasing receptor
number [140]. The changes in receptor properties appear sec-
ondary to observed alterations in cytoskeletal actin, and could
be reproduced by cytochalasin B administration. Thus it ap-
pears that intracellular acidosis can cause changes in the
cytoskeleton of renal epithelial cells, which in turn alter recep-
tor function on the plasma membrane. It is interesting to
speculate that renal cell growth observed during extracellular
acidosis likewise might be mediated through cytoskeletal alter-
ations and subsequent changes in growth factor receptors. This
phenomenon would be especially relevant to recovery of the
kidney after acute renal failure in the setting of systemic
acidosis.
Four growth factors—EGF, TGF-J3, PDGF, and FGF—each
can enhance synthesis of extracellular matrix proteins through
different mechanisms [67, 86, 141, 142]. As there are direct
connections between the extracellular matrix and cytoskeleton
via the cell proteins ankyrin and fodrin, growth factors could,
perhaps indirectly, facilitate repair of the cytoskeleton as well.
Clearly the precise role of growth factors in repair of the
cytoskeleton after acute injury remains to be defined.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): I'm very interested in the idea of increased
growth factors with counterbalancing inhibitory factors. Has
anyone measured growth factors in urine?
DR. TOBACK: About 50 g of epidermal growth factor is
excreted in the urine of normal humans each day [67]. This
represents a large amount of a factor that is biologically active.
The source of urinary EGF is not clear. It is small enough (Mr,
6045) to be easily filtered, but given the low concentration in
plasma, the amount in urine is too large to be accounted for by
filtration alone. The remainder likely originates from the kid-
ney. It is not known exactly how EGF gets into the urine, but
one possibility is that urinary proteases cleave precursor EGF
molecules that protrude from the apical surface of cells, thereby
releasing the growth factor into the tubular lumen.
DR. KING: I would think that filtered factors would be
susceptible to tubular endopeptidases.
DR. TOBACK: In principle you are right. Epidermal growth
factor does appear in the urine in two forms of 51 and 53 amino
acids in length, so the extent of cleavage of this growth factor
appears modest [67]. Perhaps the tertiary conformation of the
protein confers relative resistance to protease action.
It is interesting that the amount of mRNA encoding the EGF
precursor declines progressively from 2 to 24 hours after the
onset of ischemic acute renal failure in the rat [71]. Concur-
rently, the quantity of EGF protein in the urine falls to nearly
zero. Thus increased local production of EGF does not appear
to mediate nephron repair after injury. On the other hand, the
number of EGF receptors per renal cell rises approximately
threefold; thus, exogenous EGF delivered to the cells via the
plasma could readily stimulate them to proliferate. The in-
creased number of receptors might be an important reason why
exogenously administered EGF attenuates the course of acute
renal failure [73, 74]. Also, perhaps the pharmacologic dose of
EGF administered in these experiments exceeds the capacity of
serum and urinary proteases to degrade the growth factor so
that it reaches the tubular cells intact and induces proliferation.
DR. RONALD PERR0NE (Division of Nephrology, New En-
gland Medical Center): You show nicely that several conditions
stimulate release of growth factors from BSC-l cells in vitro.
Do maneuvers that injure cells in culture, for example, anoxic
injury, cause release of growth factors in the same kind of
conditioned-media experiments that you described for low
sodium and low potassium?
DR. TOBACK: That's a good question. We have not done the
experiment you suggest. In collaboration with Eugene Gold-
wasser and Margaret Walsh-Reitz at the University of Chicago,
we did ask whether exposure of BSC-l cells to hypoxia would
induce transcription of erythropoietin mRNA and secretion of
the protein. The answer was no. A recent report, however,
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indicates that monocyte-derived macrophages exposed to hy-
poxia release several mitogens for endothelial cells, including
basic FGF [1431.
Da. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook, Stony Brook, New
York): Do growth factors play a role in the renal hypertrophy
evoked by uninephrectomy? If so, what do you think triggers
them into action?
DR. TOBACK: This is an area of considerable interest, but the
factors that initiate renal hypertrophy after uninephrectomy
remain unknown. Insulin-like growth factor-I has been studied
as a possible mediator of this response because it is made in
renal cells and induces hypertrophy of proximal tubular cells in
culture [10]. Because the amount of the factor is elevated in the
compensating kidney 5 days after uninephrectomy, but not at
one day, it appears unlikely that IGF-I initiates compensatory
growth. Compensatory enlargement and an increase in renal
IGF-I content occur 7 days after uninephrectomy in dwarf rats
that are deficient in growth hormone [144]. Thus increased
IGF-I production in renal hypertrophy is independent of growth
hormone.
Angiotensin II possibly plays a role in renal hypertrophy
because angiotensin converting enzyme inhibitors block com-
pensatory growth after partial renal ablation in rats [110]. This
has been ascribed to changes in intrarenal hemodynamics, but
more recently other direct cellular effects of angiotensin II have
been defined, such as its capacity to stimulate hypertrophy of
proximal tubular cells in culture [114, 145].
Many attempts have been made to isolate unique substances
from blood that mediate compensatory renal growth after
uninephrectomy. A recent report describes a factor isolated
from the plasma of female rats 24 hours after uninephrectomy
[146]. This factor was partially purified by gel filtration and
high-performance liquid chromatography, and has an Mr of
17,000 to 22,000. The factor stimulates DNA synthesis in male
murine kidneys in vivo and porcine proximal tubular cells of the
LLC-PK1 line in culture. The characteristics of this factor
appear different from those of known renal growth factors.
DR. PERRONE: Polycystic kidney disease is, among other
things, a model of increased cell proliferation. I was intrigued
about your comments regarding kidney cells being tonically
inhibited. Are there any instances of cyst formation during
recovery from tubular necrosis?
DR. TOBACK: Cystic change during recovery after acute renal
failure must be quite rare, if it occurs at all. Investigators have
sought a role for growth factors in human cystic diseases
because cell proliferation is often detected in the cyst wall [147].
The concentration of EGF has been measured in fluid obtained
from patients with several types of cystic disease and found to
be intermediate between that of urine and plasma [148].
A contribution of EGF in cyst formation has been sought in
cpk mice, a model of congenital polycystic kidney disease in
which large cysts develop in collecting tubules of neonatal
animals. Unexpectedly, the amounts of preproEGF mRNA in
renal tissue and urinary excretion of EGF protein are decreased
in affected mice compared with control littermates [149]. There
may be a generalized abnormality in the regulation of the gene
encoding preproEGF in cpk mice, because the normal burst of
growth factor synthesis in the salivary glands in response to
testosterone is not seen [150]. Taken together, these observa-
tions suggest that an insufficient amount of preproEGF or EGF
protein during development might result in formation of collect-
ing duct cysts and renal failure.
DR. PERRONE: If you were to design a clinical study looking
at the efficacy of growth factors in tubular necrosis, what would
you put in the concoction?
DR. TOBACK: The strategy that I have in mind requires that
the patient first be well dialyzed. Nutrition is another critical
issue. It is important to provide calories, although the amount
will depend on the presence or absence of a catabolic state such
as sepsis or trauma, and the nutritional status of the patient.
Administration of amino acids is valuable to preserve muscle
mass by minimizing gluconeogenesis so that the infused amino
acids will serve primarily as precursors for protein synthesis
rather than as fuel. After addressing these issues, it is worth
considering several factors that could speed repair and regen-
eration of injured renal cells: (1) thyroxine promotes renal cell
growth and clearly stimulates recovery after experimental
nephrotoxic acute renal failure [151]; (2) infusion of ATP with
magnesium chloride has been shown to hasten recovery after
toxic, ischemic, and obstructive renal injury in animals [1521,
but its utility in humans remains to be determined, and (3) EGF
is a growth factor that facilitates recovery after renal tubular
injury in the rat [73—75]. The critical factors that mediate repair
of tubule structure and function probably have not yet been
discovered. For example, after we are able to purify a sufficient
amount of the low-sodium growth factor, we plan to evaluate its
potential as a therapeutic agent to accelerate renal regeneration
in vivo.
DR. HARRINOTON: When speaking about the factors that
control growth of renal epithelial cells in culture, you referred
to low-molecular-weight nutrients. To what were you referring?
DR. TOBACK: Glucose and amino acids.
DR. HARRINOTON: Would you speculate on how the signal
from the various growth factors is transmitted across the cell
membrane and intracellularly?
DR. TOBACK: Exactly how binding of a growth factor to the
extracellular domain of its receptor sends a signal to the
functional cytosolic domain of the molecule is not known.
When the growth factor binds to its receptor, it is thought that
conformational changes occur in the ligand-receptor complex
that activate the receptor's functional domain, which is often a
tyrosine kinase. The sequence of the 18 to 20 amino acids of the
receptor protein that span the plasma membrane is of particular
importance because mutations in one or more of them can alter
receptor function [1531. The ligand-activated PDGF receptor,
for example, associates with key cytosolic mediators such as
phospholipase C. The receptor then activates the enzyme by
tyrosine phosphorylation, which subsequently triggers other
signal transduction events such as production of inositol
trisphosphate and diacylglycerol [154].
DR. LIESKE: The plasma concentration of angiotensin II
increases after acute renal failure. This abnormally high angio-
tensin II concentration appears to play a role in renal vasocon-
striction and loss of autoregulation of renal blood flow. On the
other hand, angiotensin II can induce hypertrophy of proximal
tubular cells in culture and promote hyperplasia of these cells if
EGF is present. Increased EGF binding is noted after acute
renal failure in rats, so that an elevated angiotensin II concen-
tration and increased EGF binding could lead to mitogenesis
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and hastened epithelial regeneration. ACE inhibitors, by de-
creasing angiotensin II levels, could have two opposing effects
on renal function after acute renal failure: they could increase
renal blood flow and decrease renal epithelial cell proliferation.
Has anyone investigated ACE inhibitors in patients with acute
renal failure? Which cellular action of angiotensin II is more
important in vivo after acute renal failure?
DR. TOBACK: The role of the renin-angiotensin system in the
pathogenesis of acute renal failure remains controversial de-
spite much investigation [155]. Studies of ACE inhibition after
acute renal failure have centered on the immediate post-injury
period. In a dog model of mercuric-chloride-induced renal
failure, intravenous captopril preserved renal blood flow and
GFR without attenuating an elevated FENa when assessed 3
hours after the nephrotoxic insult [156]. Similarly in rats,
captopril and saralasin each were able to prevent a decline in
renal blood flow 3 hours after glycerol-induced myoglobinuric
acute renal failure, but the subsequent course of renal failure, as
assessed by measurements of BUN and creatinine concentra-
tion, was not changed by either agent [157]. The newly de-
scribed direct actions of angiotensin H on renal tubular cell
sodium transport and growth may bear on the observation that
ACE inhibition can prevent deleterious immediate changes in
renal function after acute injury, but not enhance long-term
outcome. It could well be that the hemodynamic actions of
ACE inhibition predominate in the early phases of acute renal
failure, resulting in improved renal blood flow and GFR. The
growth-promoting effect of angiotensin II on renal epithelial
cells could be blunted by ACE inhibitors despite the salutary
effect of the drug in increasing renal perfusion. The negative
cellular effect might offset the immediate benefits on hemody-
namic parameters and thereby explain the overall ineffective-
ness of ACE inhibition in acute renal failure.
Da. MADIAS: In the experiments in which EGF was given
exogenously to hasten recovery from acute renal injury, was
mitogenic activity increased in tissues other than the injured
organ?
DR. TOBACK: That's a good question. I'm not aware of any
published information on that point. EGF is a very potent
growth factor, and it would not be surprising if it had a
mitogenic effect on other organs. On the other hand, the kidney
might be particularly sensitive to the growth factor because of
the increased number of EGF receptors per cell demonstrated
in the injured nephron [71]. EGF can facilitate wound healing in
other tissues. When administered topically to the injured cor-
nea, it accelerates healing of the wounded epithelium [158].
DR. MADIAS: Have you done the reverse experiment to that
in your low-potassium study, namely, does a high-potassium
environment lead to production of a growth-inhibiting activity?
DR. TOBACK: Raising the concentration of potassium in the
culture medium of BSC-l cells stimulates DNA synthesis and
cell multiplication [159]. However, whether this is due to
synthesis and/or release of a growth factor is not known. To find
out, the excess potassium would have to be removed from the
conditioned medium, perhaps by dialysis, prior to testing for
the presence of a growth-promoting factor. We have not yet
performed that experiment.
Da. PAUL KURTIN (Director, Dialysis Unit, New England
Medical Center): The age at the time of renal injury or unine-
phrectomy in humans affects the degree of resultant hypertro-
phy in the remaining kidney. Do you have any evidence of
age-related changes in the production of, or the response to,
growth factors?
DR. TOBACK: Little information is available about this point.
In humans the concentration of EGF in urine increases to a
peak at 1 to 2 years of age and declines slowly thereafter
throughout adolescence and adulthood [67]. The concentration
is higher in females than in males and doubles during preg-
nancy. EGF in urine and renal tissue of mice is lowest during
the first 6 days of life; it then rises gradually to the adult level by
3 to 4 months. An autocrine role for EGF in renal organogenesis
and development seems unlikely because preproEGF mRNA
and EGF protein are not detectable in the organ until the
neonatal period in rodents.
DR. KURTIN: In ischemic tissues—for example the heart—
ADP levels can rise. Is there evidence that ADP can induce
growth factors in those tissues?
DR. TOBACK: Adenine nucleotides and magnesium chloride
have been infused in shock to speed recovery and minimize the
extent of tissue injury after ischemia [160]. I am not aware that
any experiments have been performed to look for production of
an adenine-nucleotide-induced growth factor by myocardial
cells.
DR. KURTIN: In chronic renal failure, there is a spectrum of
renal cells from normal to damaged to necrotic, and in that
setting we find acquired cystic disease. Would you comment on
the role of growth factors in acquired cystic disease and why
some cysts undergo malignant degeneration?
DR. TOBACK: The incidence of cell proliferation in the normal
kidney is very low, so that detection of mitotic cells in the
shrunken kidneys of patients undergoing chronic dialysis is
unexpected. One would expect only progressive fibrosis. Pon-
dering the unexpected observation that cell proliferation occurs
in the end-stage kidney might disclose new pathogenetic mech-
anisms that mediate progressive loss of renal function long after
the initial insult has occurred. I have taken a similar approach in
pointing out the value of unexpected observations by citing
exuberant cell proliferation in the case of acute renal failure
described by Oliver (Fig. 1) in this Nephrology Forum.
What is the stimulus for cell proliferation in the end-stage
kidney? The answer is not known. We recently proposed the
following scenario [25]. Dialysis often is accompanied by wide
swings in the plasma concentrations of sodium and potassium.
Furthermore, dialysis patients are often hypo- or hyperna-
tremic, and/or hypo- or hyperkalemic. Under these conditions,
the remaining renal epithelial cells might be stimulated to
proliferate as do BSC-l cells in culture exposed to altered
concentrations of electrolytes [28, 31, 32, 159]. Such perturba-
tions in the plasma potassium and/or sodium concentration
during progression of renal disease and maintenance dialytic
therapy could result in release of autocrine and paracrine
growth-stimulatory factors, and restrict secretion of growth
inhibitors by surviving renal cells. These growth factors thereby
could mediate proliferation of the remaining tubular cells, the
formation of renal cysts, and possibly malignant transforma-
tion.
Similar alterations in the serum potassium or sodium concen-
tration exist in nonrenal diseases. Why isn't there similar
evidence of renal hyperplasia? It could be that in these disease
states, tonic inhibition of renal growth is mediated by TGF-/3
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produced by renal cells. The loss of functional tubular cell mass
during renal failure could result in reduced production of
growth inhibitors so that the action of growth-stimulatory
molecules could go unopposed.
DR. MADIAS: In your judgment, are the stimulation of the
sodium/hydrogen antiporter in response to mitogenic factors
and the resultant increase in cellular sodium content and
cytosolic alkalinization critical steps for mitogenesis?
DR. TOBACK: Activation of the sodium/hydrogen antiporter
usually occurs during the onset of cell growth, but neither its
activation nor cytosolic alkalinization are sufficient to initiate
and maintain proliferation [161]. Renal epithelial cell growth in
culture has been shown to occur in the absence of antiporter
activity [1621.
DR. HARRINGTON: Have we learned enough about these
growth factors to be able to add them to the system used for the
preservation of kidneys prior to transplantation?
DR. TOBACK: I am not aware of any clinical studies address-
ing this issue, but I hope that today's discussion will induce
investigation along those lines.
DR. COHEN: You have underscored the remarkable ability of
growth factors, both known and unknown, to mediate regener-
ation and full recovery of renal epithelial structure and function
following both toxic and ischemic injury. Is there any reason to
take hope from what we know about growth factors that
glomeruli might be induced to regenerate in the aftermath of the
various glomerulonephritides? Might one reasonably speculate
that any acute or chronic renal disease other than acute renal
failure ultimately might benefit from therapeutic manipulation
at the level of growth factors?
DR. TOBACK: Glomeruli are particularly complex because
each of the three cell types, mesangial, epithelial, and endothe-
lial, is likely to produce and respond to a different array of
growth factors. Thus far, the greatest progress has been made in
the study of mesangial cells [163], but I am not aware of reports
of attempts to induce regeneration of glomerular cells following
inflammatory cell injury. When more information is amassed
about each glomerular cell type, invading macrophages and
leukocytes, and the interactions between them, therapeutic
strategies may be developed to halt cell proliferation during the
onset of glomerulonephritis, which is probably mediated in part
by growth factors. Although the number of glomeruli in the
adult kidney apparently is fixed, it is tempting to suggest that
administration of growth factor antagonists [88] or other agents
could initiate repair and regeneration of those glomerular cells
that survive the acute inflammatory insult.
Perhaps it is also worthwhile to consider the potential thera-
peutic role of growth factors in the treatment of renal carci-
noma. If a growth factor that binds only to renal tubular
epithelial cells is identified, it could be conjugated with a
cellular toxin or radioactive isotope to produce powerful, new
chemotherapeutic agents to treat these neoplasms.
Note Added in Proof
The recently described hepatocyte growth factor, which also is
synthesized in the kidney, exhibits increased gene transcription after
ischemia and might play a role in renal regeneration.
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